❮ Back to Researchers

Wanrudee Isaranuwatchai

PhD

Director, Centre for Excellence in Economic Analysis Research

Email: Wanrudee.Isaranuwatchai@unityhealth.to
Tel: 416-864-6060 ext. 77074
Other:

Research Programs

Biography

Dr. Wanrudee Isaranuwatchai is a Scientist at the Li Ka Shing Knowledge Institute of St. Michael’s Hospital.

She is an Interim Director and a Health Economist at the Centre for Excellence in Economic Analysis Research (CLEAR), a part of the HUB Health Research Solutions at St. Michael’s Hospital. She is also an Assistant Professor at the Institute of Health Policy, Management and Evaluation, University of Toronto.

Dr. Isaranuwatchai has collaborated with researchers and decision-makers in various topics areas to help communicate the value of health programs/initiatives using economic evidence. She has experience conducting economic evaluations using person-level data and decision modeling. Dr. Isaranuwatchai’s research focuses on applied economic evaluation (e.g., how to make economic evaluation more useful to researchers, health providers, and decision-makers) and health economics methods.

Recent Publications

  1. Livingston, MH, Mahant, S, Connolly, B, MacLusky, I, Laberge, S, Giglia, L et al.. Effectiveness of Intrapleural Tissue Plasminogen Activator and Dornase Alfa vs Tissue Plasminogen Activator Alone in Children with Pleural Empyema: A Randomized Clinical Trial. JAMA Pediatr. 2020; :. doi: 10.1001/jamapediatrics.2019.5863. PubMed PMID:32011642 .
  2. Isaranuwatchai, W, Teerawattananon, Y, Archer, RA, Luz, A, Sharma, M, Rattanavipapong, W et al.. Prevention of non-communicable disease: best buys, wasted buys, and contestable buys. BMJ. 2020;368 :m141. doi: 10.1136/bmj.m141. PubMed PMID:31992592 .
  3. Teerawattananon, Y, Dabak, SV, Khoe, LC, Bayani, DBS, Isaranuwatchai, W. To include or not include: renal dialysis policy in the era of universal health coverage. BMJ. 2020;368 :m82. doi: 10.1136/bmj.m82. PubMed PMID:31992542 .
  4. Donelle, L, Regan, S, Kerr, M, Zwarenstein, M, Bauer, M, Warner, G et al.. Caring Near and Far by Connecting Community-Based Clients and Family Member/Friend Caregivers Using Passive Remote Monitoring: Protocol for a Pragmatic Randomized Controlled Trial. JMIR Res Protoc. 2020;9 (1):e15027. doi: 10.2196/15027. PubMed PMID:31922492 .
  5. Chan, K, Nam, S, Evans, B, de Oliveira, C, Chambers, A, Gavura, S et al.. Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration. BMJ Open. 2020;10 (1):e032884. doi: 10.1136/bmjopen-2019-032884. PubMed PMID:31915169 PubMed Central PMC6955501.
  6. Phillips, CM, Parmar, A, Guo, H, Schwartz, D, Isaranuwatchai, W, Beca, J et al.. Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics. Cancer. 2020; :. doi: 10.1002/cncr.32697. PubMed PMID:31913522 .
  7. Bueno, M, Stevens, B, Barwick, MA, Riahi, S, Li, SA, Lanese, A et al.. A cluster randomized clinical trial to evaluate the effectiveness of the Implementation of Infant Pain Practice Change (ImPaC) Resource to improve pain practices in hospitalized infants: a study protocol. Trials. 2020;21 (1):16. doi: 10.1186/s13063-019-3782-9. PubMed PMID:31907017 PubMed Central PMC6945403.
  8. Bombard, Y, Clausen, M, Shickh, S, Mighton, C, Casalino, S, Kim, THM et al.. Effectiveness of the Genomics ADvISER decision aid for the selection of secondary findings from genomic sequencing: a randomized clinical trial. Genet. Med. 2019; :. doi: 10.1038/s41436-019-0702-z. PubMed PMID:31822848 .
  9. Isaranuwatchai, W, Redwood, O, Schauer, A, Van Meer, T, Vallée, J, Clifford, P et al.. A Remote Patient Monitoring Intervention for Patients With Chronic Obstructive Pulmonary Disease and Chronic Heart Failure: Pre-Post Economic Analysis of the Smart Program. JMIR Cardio. 2018;2 (2):e10319. doi: 10.2196/10319. PubMed PMID:31758770 PubMed Central PMC6834207.
  10. Chan, KKW, Guo, H, Cheng, S, Beca, JM, Redmond-Misner, R, Isaranuwatchai, W et al.. Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis. Cancer Med. 2020;9 (1):160-169. doi: 10.1002/cam4.2705. PubMed PMID:31724340 PubMed Central PMC6943167.
Search PubMed

Affiliations & Other Activities

  • Scientist, Li Ka Shing Institute
  • Assistant Professor, Institute for Health Policy, Management and Evaluation, University of Toronto
X